2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2234

Disability in Acute Low Back Pain: The Role of Pain Severity, Pain Catastrophizing, Depression, and Exercise
Abstract Number: 1554

Discontinuation and Switching Patterns By TNFi Line of Therapy in Patients with Psoriatic Arthritis—Results from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 1553

Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Abstract Number: 921

Discordant Patient-Physician Assessments of Disease Activity and Its Persistence Adversely Impact Quality of Life and Work Productivity in United States Hispanics with Rheumatoid Arthritis
Abstract Number: 1428

Discovery and Characterization of JNJ-61178104, a Bispecific Antibody Against Human Tumor Necrosis Factor (TNF) Alpha and Interleukin (IL)-17A
Abstract Number: 1914

Discovery of a Novel CD8+ T Cell Population in Ankylosing Spondylitis Implicates Gut-Joint Trafficking in the Disease
Abstract Number: 821

Discrepancies between Clinical- and Imaging-Based Assessments of Disease Activity in Takayasu’s Arteritis
Abstract Number: 2820

Disease Activity By the Sledai in Lupus Patients Who Self Report Sleep Disturbance and Sleep Impairment Using the Patient-Reported Outcomes Measurement Information System Instruments
Abstract Number: 2554

Disease Activity in Psoriatic Arthritis-ESR Index Maybe a Valid Tool to Evaluate Disease Activity in Patients with Psoriatic Arthritis When CRP Is Not Available
Abstract Number: 1629

Disease Activity Is an Independent Predictor of Leukopenia in a Large International SLE Cohort
Abstract Number: 347

Disease Burden at One Academic Rheumatology Routine Care Setting Is Similar in Osteoarthritis (OA) and Rheumatoid Arthritis (RA) at First Visit but Significantly Greater in OA at a 6-Month Follow-up Visit
Abstract Number: 459

Disease Course in Seronegative RA Patients Classified According to the 2010 ACR/EULAR Criteria
Abstract Number: 1363

Disease Duration and Shared Epitope, but Not Smoking History, Are Associated with Peptidylarginine Deiminase 4-Antibody Development in Rheumatoid Arthritis
Abstract Number: 450

Disease Duration and Withdrawal of Biologic Agents Predict Radiological Progression in a Cohort of Rheumatoid Arthritis Patients in Latin America. a Real World Study
Abstract Number: 2456

Disease Flares Among Early Rheumatoid Arthritis Patients Treated with Continued Methotrexate Either Alone or in Combination with Adalimumab (Humira)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].